Zupa, Rosa
Duncan, Neil
Giménez, Ignacio
Mylonas, Constantinos C.
Pousis, Chrysovalentinos
Passantino, Letizia
Cuko, Rezart
Corriero, Aldo
Funding for this research was provided by:
European Union´s Programme H2020 (GA 862658)
Article History
Received: 31 October 2022
Accepted: 24 April 2023
First Online: 28 April 2023
Competing interests
: Rosa Zupa, Neil Duncan, Constantinos C. Mylonas, Chrysovalentinos Pousis, Letizia Passantino, Rezart Cuko and Aldo Corriero declare no competing interest. Ignacio Ginenéz is associated with the biotech company Rara Avis Biotech, S. L., which produced the recombinant gonadotropin employed in this study.